Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HU6 in MASH
NCT07491458Phase 2Recruiting
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HU6 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Rivus Pharmaceuticals, Inc.. Started Feb 2026; status: recruiting.
02
Drugs
HU6
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07491458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491458.